Get the Stockscreener App
6.04
51.38%
2.05
After Hours:
6.71
0.67
+11.09%
Ernexa Therapeutics Inc stock is traded at $6.04, with a volume of 63.52M.
It is up +51.38% in the last 24 hours and up +15.21% over the past month.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
See More
Previous Close:
$3.99
Open:
$5.85
24h Volume:
63.52M
Relative Volume:
62.14
Market Cap:
$7.04M
Revenue:
$1,000
Net Income/Loss:
$-14.08M
P/E Ratio:
-5.4695
EPS:
-1.1043
Net Cash Flow:
$-7.05M
1W Performance:
+28.92%
1M Performance:
+15.21%
6M Performance:
-85.70%
1Y Performance:
-92.26%
1-Day Range:
$4.5701
$7.70
1-Week Range:
$3.1829
$7.70
52-Week Range:
$3.1829
$100.46
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Name
Ernexa Therapeutics Inc
Sector
Industry
Phone
(617) 798-6700
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
6.04 | 4.65M | 1,000 | -14.08M | -7.05M | -1.1043 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ernexa Therapeutics Inc Stock (ERNA) Latest News
Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data - TechStock²
Ernexa Therapeutics stock climbs on breakthrough preclinical data - MSN
ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results - Stocktwits
Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models - Yahoo Finance
ERNA Stock Explodes Higher As Tiny Biotech Draws Trader Focus - StocksToTrade
ERNA Stock Rockets Higher As Traders Target Breakout Move - timothysykes.com
Ernexa reports preclinical data for ovarian cancer therapy - Investing.com
Ernexa reports preclinical data for ovarian cancer therapy By Investing.com - Investing.com Canada
Ernexa stock surges 40% on ovarian cancer trial results By Investing.com - Investing.com Canada
Ernexa Therapeutics Unveils Breakthrough Preclinical - GlobeNewswire
ERNAW Ernexa to share quarterly earnings context and updated clinical pipeline progress with investors this month.Investment Community Signals - Newser
Eterna Therapeutics Implements 1-for-25 Reverse Stock Split - TipRanks
Ernexa Therapeutics announces 1-for-25 reverse stock split; shares down - MSN
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split - marketscreener.com
ERNAW (Ernexa Therapeutics) Shiller PE Ratio : (As of Apr. 27, 2026) - GuruFocus
ERNAW (Ernexa Therapeutics) Cyclically Adjusted PS Ratio : (As of Apr. 22, 2026) - GuruFocus
Is Ernexa Therapeutics (ERNA) stock showing breakout potential (Loses Ground) 2026-04-20Crowd Entry Signals - Newser
ERNAW | Ernexa Therapeutics Inc. Warrants Insider Trading - Quiver Quantitative
Is Ernexa (ERNAW) Stock Ready to Move | Price at $0.04, Down 29.86%Trader Community Insights - Newser
ERNA Should I Buy - Intellectia AI
Is Ernexa Therapeutics Inc in a long term uptrend2026 Market Outlook & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Institution Moves: Can Ernexa Therapeutics Inc continue delivering strong returns2026 Short Interest & Low Drawdown Trading Techniques - baoquankhu1.vn
Analyst Calls: Is Ernexa Therapeutics Inc stock a good pick for beginners2026 Levels & Fast Moving Trade Plans - baoquankhu1.vn
Signal Recap: Will Ernexa Therapeutics Inc outperform tech stocksPrice Action & AI Driven Stock Reports - baoquankhu1.vn
Is Ernexa (ERNAW) Stock Slowing Down | Price at $0.06, Up 96.67%Fundamentals - Newser
Chart Watch: Will Ernexa Therapeutics Inc outperform tech stocks2026 Top Gainers & Precise Buy Zone Identification - baoquankhu1.vn
ERNA PE Ratio & Valuation, Is ERNA Overvalued - Intellectia AI
Is Ernexa Therapeutics (ERNA) Stock Overvalued Now | Price at $0.20, Down 4.76%Long Term Investing - Newser
Ernexa Therapeutics (NASDAQ: ERNA) OKs Board-authorized 1-for-10–1-for-25 reverse split - Stock Titan
ERNAW Technical Analysis | Trend, Signals & Chart Patterns | ERNEXA THERAPEUTICS INC31 (NASDAQ:ERNAW) - ChartMill
ERNEXA THERAPEUTICS INC31 (ERNAW) Stock Chart - ChartMill
Ernexa plans ovarian cancer trial for cell therapy ERNA-101 By Investing.com - Investing.com Canada
Deep tumor regressions put Ernexa on track for 2026 human trial - Stock Titan
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 - GlobeNewswire
[EFFECT] Ernexa Therapeutics Inc. SEC Filing - Stock Titan
Momentum Shift: Is Ernexa Therapeutics Inc a strong candidate for buy and holdLayoff News & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Eterna Therapeutics Faces Nasdaq Delisting Risk After Notice - The Globe and Mail
Ernexa Therapeutics Inc. Files Form 8-K: Notice of Nasdaq Delisting and Company Response – March 2026 - Minichart
Ernexa Therapeutics receives Nasdaq delisting notice due to minimum bid price By Investing.com - Investing.com India
Ernexa Therapeutics receives Nasdaq delisting notice due to minimum bid price - Investing.com Australia
Ernexa Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Resistance Check: Is PAVmed Inc stock a value trap2026 Key Lessons & Precise Buy Zone Tips - baoquankhu1.vn
AI Stocks: Why is Ernexa Therapeutics Inc stock going upTrade Risk Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
Ernexa Therapeutics Inc may offer up to $50 million of securitiesSEC filing - marketscreener.com
Ernexa Therapeutics IncMay Offer Up To $50 Million Of SecuritiesSEC Filing - TradingView
Ernexa Therapeutics Inc. 2025 Annual Report: Synthetic Allogeneic iMSC Therapy, Business Overview, Key Risks, and Patent Portfolio - Minichart
Ernexa Therapeutics 2025 10-K: $0.0M Revenue, Net Loss $(14.08)M - TradingView
Ernexa Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Tranche Update on Ernexa Therapeutics Inc.'s Equity Buyback Plan announced on November 25, 2024. - marketscreener.com
Aug Wrap: Is Ernexa Therapeutics Inc exposed to currency risksPortfolio Growth Summary & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Ernexa Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Ernexa Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ernexa Therapeutics Inc Stock (ERNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cherington Charles | 10% Owner |
Jun 09 '25 |
Buy |
0.10 |
21,241,163 |
2,221,826 |
41,659,743 |
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):